Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.
Joseph Laplume, the Executive Vice President of Corporate Strategy & Development at Charles River Laboratories International Inc (NYSE:CRL), has recently sold 1,850 shares of the company's stock.
Charles River (CRL) and GC4K announce a gene therapy manufacturing collaboration.